The present invention relates to a
galantamine analog having a
cholinesterase inhibitory activity, and a preparation method therefor and the use thereof. The
galantamine analog has a general
structural formula as shown in formula (IA), (IB) or (IC). In formula (IA), R1 is selected from
hydrogen, o-fluoro, m-fluoro, p-fluoro, 2,4-difluoro, m-
trifluoromethyl, p-methyl, 3,5-dimethoxy, p-chloro, p-nitro, p-cyano or p-trifluoromethoxy. In formula (IB), R2 is selected from phenyl, o-fluorophenyl, m-fluorophenyl, p-fluorophenyl, 2,4-difluorophenyl, 3,5-difluorophenyl, o-methylphenyl, p-methylphenyl, p-methoxyphenyl, indole, p-cyanophenyl, p-trifluoromethylphenyl, p-trifluoromethoxyphenyl, p-nitrophenyl or
naphthalene ring. In formula (IC), R3 is selected from
hydrogen, o-fluoro, m-fluoro, p-fluoro, m-chloro, p-chloro, p-methyl, o-methoxy, m-methoxy or p-methoxy. The
galantamine analog of the present invention has a
cholinesterase inhibitory activity superior to that of galantamine, and is expected to be used for treating diseases associated with
cholinergic dysfunction.